PharVision Advisers’s Amcor AMCR Stock Holding History

PharVision Advisers’s Portfolio AMCR Stock Details AMCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-5,480	Closed	-$252K	–	664
2025 Q2	$252K	Sell	5,480 -691	-11%	-$31.9K	0.36%	134
2025 Q1	$299K	Buy	+6,171	New	+$304K	0.42%	94

Other funds holding AMCR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PharVision Advisers's AMCR Position: Q3 2025 in Review

PharVision Advisers sold out of Amcor (AMCR) in Q3 2025, closing a stake of 5,480 shares — an estimated $252K sold.

PharVision Advisers first reported a position in AMCR in Q1 2025 and held it in 2 quarters. The position peaked at $299K in Q1 2025. 772 funds tracked by Wall St. Rank hold AMCR as of Q3 2025.

PharVision Advisers reported no remaining Amcor position as of Q3 2025 after selling out during the quarter.
PharVision Advisers sold 5,480 Amcor shares in Q3 2025, an estimated $252K.
PharVision Advisers first reported a position in Amcor in Q1 2025 and held it in 2 quarters.
PharVision Advisers's Amcor position peaked at $299K in Q1 2025.
772 funds tracked by Wall St. Rank held Amcor as of Q3 2025.

Based on PharVision Advisers's 13F filing for Q3 2025, filed 17 Nov 2025.